SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel Post author: Post published:December 12, 2023 Post category:uncategorized SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. You Might Also Like Lymphovenous anastomosis may be an effective treatment for Alzheimer’s disease February 26, 2026 Study finds no benefit of stronger antibiotics for sinusitis April 20, 2026 Finerenone shows promise for heart failure with mildly reduced or preserved ejection fraction September 2, 2024
Finerenone shows promise for heart failure with mildly reduced or preserved ejection fraction September 2, 2024